Compare Amplitude Inc (AMPL) vs Medpace Holdings Inc (MEDP) Price & Performance

AMPL trades at $12.38, up 1.56% with bullish technical signals from moving averages and ADX indicators. The company shows strong revenue growth reaching $343M in 2025 with a 72% gross margin, though it continues to report net losses. Recent Q2 2026 results missed EPS expectations but beat revenue estimates, with management highlighting AI analytics platform growth and enterprise customer expansion as key drivers.

While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, investors face execution risks from persistent losses, negative cash flow, and ongoing fraud investigations. The stock's valuation appears stretched at 11.6x book value, requiring successful monetization of AI initiatives to justify current levels.

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.